LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Lista de Ações・MediciNova Inc

MediciNova Inc

Fechado

SetorSaúde

1.31

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.28

Máximo

1.32

Indicadores-chave
By Trading Economics
Rendimento	216K -2.6M
Vendas	35K 187K
EPS	-0.05
Margem de lucro	-1,383.144
Funcionários	6
EBITDA	63K -2.8M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+506.06% upside

Dividendos
By Dow Jones
Próximos Ganhos	12 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-2M 67M
Abertura anterior	1.31
Fecho anterior	1.31

Sentimento de Notícias

By Acuity

26%

74%

59 / 344 Ranking em Healthcare

MediciNova Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de jun. de 2026, 21:51 UTC

Grandes Movimentos do Mercado

Merlin Shares Rally After Defense Department's Design Review Wraps

4 de jun. de 2026, 23:46 UTC

Conversa de Mercado

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 de jun. de 2026, 23:44 UTC

Conversa de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 de jun. de 2026, 23:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 de jun. de 2026, 23:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Energy Resources of Australia to Enter Trading Halt

4 de jun. de 2026, 23:34 UTC

Conversa de Mercado

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 de jun. de 2026, 23:31 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 de jun. de 2026, 23:31 UTC

Conversa de Mercado

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 de jun. de 2026, 23:31 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

4 de jun. de 2026, 23:08 UTC

Conversa de Mercado

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 de jun. de 2026, 22:41 UTC

Conversa de Mercado

Australia Shares Set to Rise at the Open -- Market Talk

4 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

4 de jun. de 2026, 20:44 UTC

Aquisições, Fusões, Aquisições de Empresas

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 de jun. de 2026, 20:16 UTC

Conversa de Mercado

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 de jun. de 2026, 20:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 de jun. de 2026, 19:46 UTC

Conversa de Mercado

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 de jun. de 2026, 19:38 UTC

Conversa de Mercado

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 de jun. de 2026, 19:30 UTC

Conversa de Mercado

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 de jun. de 2026, 18:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 de jun. de 2026, 18:38 UTC

Ganhos

Money Quote: Tech Weakness in Context -- WSJ

4 de jun. de 2026, 18:24 UTC

Ganhos

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 de jun. de 2026, 17:09 UTC

Conversa de Mercado

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 de jun. de 2026, 16:58 UTC

Ganhos

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 de jun. de 2026, 16:46 UTC

Conversa de Mercado

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 de jun. de 2026, 16:38 UTC

Ganhos

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

4 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

4 de jun. de 2026, 16:13 UTC

Conversa de Mercado

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 de jun. de 2026, 16:11 UTC

Conversa de Mercado

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 de jun. de 2026, 15:56 UTC

Conversa de Mercado

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Comparação entre Pares

Variação de preço

MediciNova Inc Previsão

Preço-alvo

By TipRanks

506.06% parte superior

Previsão para 12 meses

Média 8 USD 506.06%

Máximo 10 USD

Mínimo 6 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para MediciNova Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

Comprar

Manter

Vender

Com base em 2 analistas que deram avaliações de ações para MediciNova Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

59 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.